Argus
http://www.argusresearch.com/Argus is an independent equity research firm with approximately 500 leading US companies across more than 60 industries in its coverage universe. The firm employs a simple Buy, Hold, and Sell rating system to reflect its outlook on companies.
View Older Stories View More Recent Stories
-
Second Sight Medical Products, Inc. Announces Warrants Approved for Listing on Nasdaq With Trading Scheduled to Commence March 29 under Symbol “EYESW”
-
Second Sight Reports Fourth Quarter and Year End 2016 Financial Results
-
Second Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering
-
Second Sight Appoints David Jacques as Vice President of Research and Development
-
Second Sight to Discuss Fourth Quarter and Year-End 2016 Financial Results on March 9, 2017 Conference Call
-
Second Sight Announces Professor Stanislao Rizzo Has Completed His 30th Implant of the Argus II Retinal Prosthesis
-
Second Sight Medical Products, Inc. Announces Record Date, Subscription Pricing, Expiration Date for Rights Offering and Effectiveness of Its Registration Statement
-
Second Sight Medical (EYES) Announces Positive Reimbursement Renewal Decision for Argus II in Germany
-
Second Sight Announces Positive Reimbursement Renewal Decision in Germany
-
Second Sight Medical Products, Inc. Announces Rights Offering
-
Rodman & Renshaw Reiterates Bullish View on Second Sight Medical (EYES) Following UK Government Funding for Argus II
-
Pre-Open Stock Movers 12/22: (TKAI) (GSAT) (EYES) Higher; (OVAS) (RHT) (MLHR) Lower (more...)
-
Second Sight Medical (EYES) Reports UK Government Funding for Argus II
-
UK Government Announces Funding for Second Sight’s Argus II “Bionic Eye”
-
Second Sight Reports Third Quarter 2016 Financial Results
-
Second Sight Medical (EYES) Announces Finalized CMS Medicare Outpatient Rate for Argus II
-
Second Sight Announces Final CMS Hospital Outpatient Payment Rate for 2017 and Two New CPT Codes for Programming the Argus II Retinal Prosthesis System
-
Second Sight to Discuss Third Quarter 2016 Financial Results on November 2, 2016 Conference Call
-
Second Sight (EYES) Implants Wireless Visual Cortical Stimulator in First Human Subject
-
Second Sight Announces Successful Implantation and Activation of Wireless Visual Cortical Stimulator in First Human Subject
-
Second Sight to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
-
Second Sight Medical (EYES) Announces Distribution Agreements to Bring the Argus II Retinal Prosthesis to Taiwan and Iran
-
Second Sight Reports Second Quarter 2016 Financial Results
-
Second Sight Announces Two Exclusive Distribution Agreements to Bring the Argus II Retinal Prosthesis to Taiwan and Iran
-
Second Sight Medical (EYES) Ticks Higher Following Duplicate PR
-
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
-
Pre-Open Stock Movers 07/22: (PBYI) (EYES) (PFPT) (AMD) Higher; (OPTT) (OLN) (SKX) Lower (more...)
-
After-Hours Stock Movers 07/21 (PBYI) (EYES) (PFPT) Higher; (SKX) (ATHN) (P) Lower (more...)
-
Second Sight Medical (EYES) Reports Positive Five-Year Data for Argus II
-
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
-
Second Sight to Discuss Second Quarter 2016 Financial Results on July 28, 2016 Conference Call
-
Second Sight Medical (EYES) Plans Mid-2017 Debut of Upgraded Device - CEO McGuire
-
Unusual 11 Mid-Day Movers 7/7: (LEDS) (USEG) (AVG) Higher; (GPL) (SEV) (FLSR) Lower
-
Pre-Open Stock Movers 07/07: (LEDS) (AVG) (WWAV) Higher; (FSLR) (ARE) (ROIC) Lower (more...)
-
Second Sight Medical (EYES) Reports CMS Proposed Rate of Approximately $150,000 for Argus II
-
Second Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering
-
Second Sight Files S-1 Registration Statement for Rights Offering to Shareholders and Sets Record Date
-
Second Sight Reports First Quarter 2016 Financial Results
-
Second Sight to Discuss First Quarter 2016 Financial Results on April 28, 2016 Conference Call
-
Second Sight (EYES) Announces Positive Recommendation for NHS England Funding of Argus II Bionic Eye
-
Second Sight Appoints Steven D. Okland Jr. as Commercial Vice President, U.S. and Canada
-
Second Sight to Present at the 28th Annual ROTH Conference on March 14, 2016
-
Second Sight Medical (EYES) Tops Q4 EPS by 1c
-
Second Sight Reports Fourth Quarter and Year End 2015 Financial Results
-
Second Sight to Discuss Fourth Quarter and Year End 2015 Financial Results on March 3, 2016 Conference Call
-
Second Sight Medical (EYES) Mourns Loss of Founder Alfred E. Mann
-
Second Sight Mourns Loss and Celebrates Legacy of Founder Alfred E. Mann
-
Unusual 11 Mid-Day Movers 2/23: (NEWP) (HLX) (MOMO) Higher; (PTCT) (CHGG) (ONDK) Lower
-
Second Sight Medical (EYES) to Unveil Five-Year Outcomes Associated With Argus II
-
Second Sight to Announce Five-Year Data from Argus II Clinical Trial Program

